Curriculum Vitae
Herbert Greenman, MD

Practice Address:
Greenman Eye Associates
2801 Randolph Road, Suite 200
Charlotte, NC 28211
hgreenman@greenmaneyeassociates.com

Site Affiliation:
2023
DJL Clinical Research, PLLC
431 N Wendover Rd
Charlotte, NC 28211

Education:

2003-2004	OCLI Cornea Fellowship Nassau University Medical Center East Meadow, New York
2000-2003	Residency in Ophthalmology Duke University Durham, North Carolina
1999-2000	Preliminary Medicine Program Cabrini Medical Center New York, New York
1999	Doctor of Medicine Duke University Medical School Durham, North Carolina
1995	BA, Summa Cum Laude Major: Biological Basis of Behavior Field of Concentration: Neural Science University of Pennsylvania Philadelphia, Pennsylvania

Professional Experience:

2007-Present	Consulting Assistant Clinical Professor, Dept of Ophthalmology Duke University
2004-Present	Ophthalmologist Greenman Eye Associates
2004-2007	Assistant Clinical Professor, Dept of Ophthalmology University of South Carolina Columbia

Licensure/Certifications:

2005-Present	American Board of Ophthalmology

Awards:

2003	Duke University Eye Center Award for Ocular Innovation and Research
1995	Benjamin Franklin Scholar

Publications:

- **Greenman, H.** The Optimal Number of Biometric measurements to Obtain the Most Accurate Post-Cataract Surgery Vision July 2021 ASCRS Poster
- Perry HD, Solomon R, Donnenfeld ED, Perry AR, Wittpenn JR, **Greenman HE,** Savage HE. Evaluation of topical cyclosporine for the treatment of dry eye disease.Arch Ophthalmol. 2008 Aug;126(8):1046-50.
- Solomon R, Perry HD, Donnenfeld ED, **Greenman H.** Slit Lamp Biomicroscopyof the Tear Film of Patients Using Topical Cyclosporine A 0.05% (Restasis)and Refresh Endura - A New Finding. J Cataract Refract Surg May 2005.
- **Greenman, H.,** Perry, H., Solomon, R., Donnenfeld, E.Conjunctival Autograft for Mitomycin-C-Induced Ocular Surface Failure ASCRS Poster 2004
- **Greenman, H.,** Donnenfeld, E, Perry, H., Etemandi H., Snyder R., Aqueous humor gatifloxacin levels with intracameral and topical treatment following cataract surgery in a rabbit model ARVO Abstract 2004
- **Greenman, H.** Woodward, J. The Safety of Substances Used During CO2 Laser Surgery. ARVO Abstract 2003.
- **Greenman, H.,** Lai, J.C. Contemporary Management of Hyphema. Contemporary Ophthalmology 2002 (19): 1-6.
- **Greenman, H.,** Herndon, L., Epstein, D.L., Stinnett, S., Challa, P. The Effects of Drying on Central Corneal Thickness. ARVO Abstract 2002

Clinical Research:

Clinical Investigator - Dehydrex Study: Concentrated dextran solution the treatment for recurrent epithelial erosion syndrome

Clinical Investigator - RTOG3508/Abbvie M13-813: Blinded Phase 2b/3 Study in Subjects with Newly Diagnosed GBM

Clinical Investigator - AbbVie M16-534: Phase 3b Study for Management of Ocular Side Effects in Subjects with EGFR-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)

Clinical Investigator - GSK 205678 - A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of two doses of the Antibody Drug Conjugate GSK2857916 in Participants with Multiple Myeloma Who had 3 or more prior lines of treatment, Are Refractory to proteasome inhibitor, and immunomodulatory agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)

Clinical Investigator - A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination with Pembrolizumab in Subjects with Relapsed/Refractory Multiple Myeloma (DREAMM 4)

Clinical Investigator - Boehringer Ingelheim: A Phase I Open-label Dose Escalation Trial of BI 1701963 as Monotherapy and in Combination With Trametinib in Patients With KRAS Mutated Advanced or Metastatic Solid Tumours

Clinical Investigator – Incyte: A Phase I/II Study of Carfilzomib, Lenalidomide, Dexamethasone and the Anti-BCell Maturation Antigen (BCMA) Antibody Drug Conjugate Belantamab Mafodotin in Multiple Myeloma

Ophthalmologist – Idorsia Pharmaceuticals: A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE). CARE: Cenerimod Assessing S1P1 Receptor modulation in Systemic Lupus Erythematosus

Ophthalmologist – Incyte: A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy and safety of INCB054828 in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 translocations who failed previous therapy

Ophthalmologist – Incyte: An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib

Ophthalmologist – Idorsia: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE)

My signature verifies the information in this document is accurate and updated appropriately.

Signature

4/4/23
Date